BLOG / 🇮🇳 India / index intelligence · · daily

BSE Pharma Sector Regulatory Filings — October 23, 2026

India BSE PHARMA

By Gunpowder Editorial ·

4 high priority 10 medium priority 14 total filings analysed

Executive Summary

Across the 14 filings for the BSE PHARMA stream (all dated 23 October 2026), the dominant theme is a sharp divergence between headline top-line growth and bottom-line pressure. Torrent Pharmaceuticals' Q2 FY27 revenue rose 51% YoY to Rs. 4,979 crore, but largely through the J.B.

Chemicals consolidation (Rs. 1,086 crore), while base business grew 18% and PAT fell 9.6% YoY as finance costs (Rs. 300 crore vs Rs. 48 crore) and D&A (Rs. 609 crore vs Rs. 204 crore) rose sharply. Dr. Reddy's Laboratories shows the same pattern at a larger scale: Q2 FY27 revenue was down 1.5% YoY but up 7.4% QoQ, consolidated net profit fell 31-36% YoY, gross margin slipped to 52.1% from 54.7%, and the company is still managing a semaglutide API quality issue, FDA Form 483 observations and a Form 2953 records assessment, with North America base business (ex-lenalidomide) growing double digits. Positive regulatory and clinical news came from Cipla (zero Form 483 observations at the InvaGen Hauppauge site) and Sun Pharma (UNLOXCYT long-term data at ESMO 2026 on 24 October). The filing flow is dominated by earnings-calendar governance items (Glenmark results 5 November, Max Healthcare results 30 October, trading-window closures) that set up a dense results cycle over the next two weeks, and a governance note on Dr. Reddy's related-party appointment of Akhil Ravi effective 13 November 2026. Overall, the sector is showing operating resilience in branded and emerging markets alongside margin and cost pressure from integration, finance costs and US generic headwinds.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance

Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from October 22, 2026.

Investment Signals (11)

  • Dr. Reddy's Laboratories ↓ (BULLISH)
    ▲

    North America base business excluding lenalidomide grew double digits while reported NA revenue fell 23% YoY on lower lenalidomide sales including a Rs. 453 Cr shelf-stock impact; gross margin recovered to 52.1% from 46.5% QoQ

  • Torrent Pharmaceuticals ↓ (BULLISH)
    ▲

    Base India business grew 20% to Rs. 2,181 crore vs IPM growth of 12%, with Gx Semaglutide holding a 32% Q2 FY27 market share

  • Torrent Pharmaceuticals ↓ (BULLISH)
    ▲

    Base Brazil revenue rose 38% to Rs. 440 crore (+20% constant currency) and US revenue rose 24% to Rs. 417 crore (+13% constant currency), showing broad-based base-business momentum

  • Cipla ↓ (BULLISH)
    ▲

    USFDA routine cGMP inspection at InvaGen's Hauppauge facility (19-22 Oct 2026) concluded with zero Form 483 observations, a clean outcome for a US manufacturing site

  • Sun Pharmaceutical ↓ (BULLISH)
    ▲

    UNLOXCYT (cosibelimab) long-term data at ESMO 2026 show ORR of 44.4%-53.1% and low grade-3 immune-related AEs (2.9%, no grade 4); two-year response probability of 69%-82% among responders, supporting the approved U.S. asset's profile

  • Dr. Reddy's Laboratories ↓ (BEARISH)
    ▲

    Consolidated H1 FY27 other income fell 51.8% YoY in Q2 to Rs. 1,562 mn, and standalone PAT rose 79.6% YoY on a low prior-year tax-adjusted base, so headline earnings quality is hard to read until the base normalises

  • Torrent Pharmaceuticals ↓ (BEARISH)
    ▲

    Q2 FY27 PAT fell 9.6% YoY to Rs. 534 crore and H1 PAT fell 3.4% despite 52.8% H1 revenue growth, as finance costs rose ~6x and D&A ~3x; Germany revenue down 7% on a third-party supplier disruption and lost high-volume tenders

  • Dr. Reddy's Laboratories ↓ (BEARISH)
    ▲

    Q2 FY27 consolidated PBT fell about 33% YoY to Rs. 12,277 mn (PBT margin 14.2% vs 20.8%) and H1 net profit fell 50.5%, with the Q1 FY27 Rs. 2,397 mn semaglutide API inventory provision still weighing on comparisons

  • Dr. Reddy's Laboratories ↓ (BEARISH)
    ▲

    PSAI (API) revenue fell 12% YoY and PSAI gross margin compressed to 9.5% from 18.0%, while Europe was flat (+1%), signalling weakness in the API and European segments

  • Glenmark Pharmaceuticals ↓ (NEUTRAL)
    ▲

    Board meeting on 5 Nov 2026 to approve Q2/H1 FY27 unaudited results, with the trading window closed since 1 Oct and reopening 8 Nov; event-driven positioning ahead of results

  • Max Healthcare Institute ↓ (NEUTRAL)
    ▲

    Q2/H1 FY27 results to be declared 30 Oct 2026 with an earnings call on 3 Nov at 12:00 noon IST; the filing contains no financial figures so no period comparison is possible yet

Risk Flags (8)

Opportunities (8)

  • Torrent Pharmaceuticals/Base Business Re-rating↓ (OPPORTUNITY)
    ◆

    Base business revenue up 18% (India +20%, Brazil +38% reported, US +24%) ex-acquisition; as integration costs normalise and D&A stabilises, the base growth profile could drive earnings recovery

  • Torrent Pharmaceuticals/Semaglutide Gx Franchise↓ (OPPORTUNITY)
    ◆

    32% Q2 FY27 market share in Gx Semaglutide in India provides a scalable growth leg within the expanded India business

  • Dr. Reddy's Laboratories/Recovery Trajectory↓ (OPPORTUNITY)
    ◆

    Sequential revenue growth of 7.4% QoQ and gross margin recovery from 46.5% to 52.1% QoQ suggest the trough may be behind the company as shelf-stock and provision effects roll off

  • Dr. Reddy's Laboratories/North America Base Business↓ (OPPORTUNITY)
    ◆

    Double-digit growth in the North America base business excluding lenalidomide shows underlying franchise strength masked by the reported decline

  • Sun Pharmaceutical/UNLOXCYT Commercial Catalyst↓ (OPPORTUNITY)
    ◆

    ESMO 2026 presentation on 24 Oct 2026 (poster 2489P, 12:00-12:45 CEST) with strong ORR and durability data (two-year response probability 69%-82%) could support the U.S. launch narrative for the oncology asset

  • Cipla/US Manufacturing Credibility↓ (OPPORTUNITY)
    ◆

    Zero Form 483 observations at the InvaGen Hauppauge site strengthens the company's US compliance record, relevant as peers face FDA observations

  • Glenmark Pharmaceuticals/Earnings Event↓ (OPPORTUNITY)
    ◆

    Q2 FY27 results on 5 Nov followed by earnings call on 6 Nov (8:30-9:30 am IST) offer a near-term catalyst for re-rating if guidance or margin trends surprise positively

  • Max Healthcare/Earnings Catalyst↓ (OPPORTUNITY)
    ◆

    Results on 30 Oct and earnings call on 3 Nov provide the next read on hospital volume and margin trends in a sector where the company's PPP and network exposures are distinct

Sector Themes (6)

  • Integration Costs Dilute Headline Growth
    ◆

    Torrent's Q2 revenue +51% YoY versus PAT -9.6% YoY, with finance costs and D&A up roughly 6x and 3x, shows that acquisition-led growth in Indian pharma is masking earnings dilution in the near term; investors should separate base-business growth from consolidation effects

  • Divergence Between Top-Line and Bottom-Line in Pharma Majors
    ◆

    Dr. Reddy's shows revenue down 1.5% YoY but net profit down 31-36% YoY, and H1 net profit down 50.5%; sector majors are seeing margin pressure from API quality costs, SG&A inflation and lower other income, even as sequential revenue improves

  • US Generic Erosion and Lenalidomide Dependence
    ◆

    Both Dr. Reddy's (NA -23% reported) and Torrent (Germany -7%, JB international -7%) show exposure to declining generic franchises and tender losses in developed markets, while emerging markets (Torrent Brazil +38%, India +20%) provide offsetting growth

  • Regulatory Quality Scrutiny Persists
    ◆

    Dr. Reddy's faces an open semaglutide API quality issue, FDA Form 483 observations and a Form 2953 records assessment, while Cipla reports zero Form 483 observations; the contrast highlights how FDA inspection outcomes are increasingly driving relative valuation within the sector

  • Governance and Related-Party Scrutiny
    ◆

    Dr. Reddy's related-party appointment (Akhil Ravi, son-in-law of the Co-Chairman) and the coordinated sequence of trading-window closures and earnings-call scheduling across Glenmark, Max Healthcare and Torrent reflect a dense disclosure cycle as Q2 FY27 results roll out between 30 Oct and 8 Nov 2026

  • Innovation Pipeline Visibility
    ◆

    Sun Pharma's UNLOXCYT data at ESMO 2026 and Torrent's semaglutide share gains point to specialty and GLP-1 franchises as the main sources of differentiated growth, with clinical durability data driving near-term narrative more than reported earnings

Watch List (8)

Filing Analyses (14)
Torrent Pharmaceuticals Limited Market Update mixed materiality 8/10

23-10-2026

Torrent Pharmaceuticals reported consolidated revenue from operations of Rs. 4,979 crore for Q2 FY27 (quarter ended 30 September 2026), up 51% YoY, with Operating EBITDA of Rs. 1,666 crore (33.5% margin, up 54% YoY). Net profit after tax was Rs. 534 crore, down 9.6% YoY from Rs. 591 crore, and the company attributes part of the revenue strength to the consolidation of J.B. Chemicals (acquired January 2026, amalgamated effective July 2026), which contributed Rs. 1,086 crore of revenue; base business revenue rose 18% to Rs. 3,893 crore. Performance is mixed: Germany revenue fell 7% and JB's international business declined 7% in the quarter, and a transient post-merger integration impact weighed on JB revenues.

  • · Half-year (H1 FY27) consolidated revenue was Rs. 9,900 crore, up 52.8% YoY, while H1 PAT was Rs. 1,100 crore, down 3.4% YoY.
  • · India base business revenue grew 20% to Rs. 2,181 crore vs IPM growth of 12%; Gx Semaglutide holds a 32% Q2 FY27 market share.
  • · Brazil revenue rose 38% to Rs. 440 crore (constant currency +20%), and US revenue rose 24% to Rs. 417 crore (constant currency +13%).
  • · Net profit margin compressed to 10.7% in Q2 FY27 from 17.9% a year earlier, reflecting higher finance costs and depreciation/amortisation after the acquisition.
  • · Standalone finance costs rose to Rs. 287 crore (Q2 FY27) from Rs. 37 crore a year earlier, and depreciation to Rs. 587 crore from Rs. 189 crore.
  • · Inventory write-off of Rs. 19 crore arose from a fire at an erstwhile JB Pharma warehouse; the related insurance claim is under assessment.
  • · Secured non-convertible debentures aggregate Rs. 10,990 crore as at 30 September 2026, with security cover of 1.41x per the Annexure disclosure, above the 110% covenant threshold referenced in the notes.
  • · The financial results exclude stamp duty payable on the amalgamation, pending adjudication by the appropriate authority.
Torrent Pharmaceuticals Limited Corporate Governance mixed materiality 8/10

23-10-2026

Torrent Pharmaceuticals reported Q2 FY27 consolidated revenue from operations of Rs. 4,979 crore, up 51% YoY, with operating EBITDA of Rs. 1,666 crore (33.5% margin, up 54% YoY). Net profit after tax was Rs. 534 crore, down 9.6% YoY from Rs. 591 crore, reflecting post-merger integration effects from the J.B. Chemicals (JB Pharma) amalgamation and higher finance and depreciation costs. Base India business grew 20% and Base Brazil grew 38% reported, while Germany revenues declined 7%, and JB business international revenues fell 7% in the quarter.

  • · Gross margin 75.4% (vs 75.8% in Q2 FY26); R&D spend Rs. 211 crore, up 35% YoY
  • · Finance costs rose to Rs. 300 crore in Q2 FY27 from Rs. 48 crore, and depreciation and amortisation rose to Rs. 609 crore from Rs. 204 crore, reflecting acquisition-related costs
  • · Germany revenue declined 7% on supply disruption at a third-party supplier and loss of certain high-volume tenders
  • · Post-merger integration caused a transient impact on JB business revenues in Q2 FY27
  • · Standalone net profit for Q2 FY27 was Rs. 498 crore, down from Rs. 597 crore in Q2 FY26
  • · Non-controlling interest relating to JB Pharma was derecognised; the amalgamation has no material impact on consolidated results per the company
  • · Stamp duty payable on the Scheme of Amalgamation is pending adjudication and is not reflected in the results
  • · Inventory write-off of Rs. 19 crore from a fire at an erstwhile JB Pharma warehouse; insurance claim under assessment
  • · Auditor's limited review report issued without qualification; Q2 FY27 consolidated results are unaudited
Sun Pharmaceutical Industries Limited Market Notice positive materiality 4/10

23-10-2026

Sun Pharmaceutical Industries filed a Regulation 30 intimation enclosing a press release announcing that updated long-term efficacy and safety data for UNLOXCYT (cosibelimab-ipdl) from the pivotal CK-301-101 trial will be presented at ESMO 2026 in Madrid on October 24, 2026. Across 205 patients, the company reports an objective response rate of 44.4%-53.1% and complete response rates of 16.7%-34.4% across three cohorts, with a low rate of high-grade immune-related adverse events (2.9% grade 3, no grade 4). The release does not disclose any financial figures, and the data remain an efficacy/safety update for a drug already approved in the U.S. (FDA, 2024).

  • · Poster presentation 2489P is scheduled for October 24, 2026, 12:00-12:45pm CEST, presented by Dr. Eva Muñoz-Couselo
  • · Median progression-free survival was 7.9 months (Group 1), 37.3 months (Group 2), and 6.1 months (Group 3); Group 1 median overall survival was 37.2 months, not reached in Groups 2 and 3
  • · Estimated probability of remaining in response at two years among responders ranged from 69% to 82% across cohorts
  • · Dosing: 1,200 mg intravenous infusion over 60 minutes every 3 weeks; approved by FDA in 2024
  • · Sun Pharma continues to explore expanding UNLOXCYT access outside the U.S.
  • · Group 1 PFS (7.9 months) and Group 3 PFS (6.1 months) are short relative to Group 2, and Group 3 ORR (44.4%) is the lowest of the three cohorts, which the release does not highlight
Glenmark Pharmaceuticals Limited Analyst/Investor Meet neutral materiality 2/10

23-10-2026

Glenmark Pharmaceuticals Limited has intimated under Regulation 30 of the SEBI LODR Regulations that its earnings call to discuss unaudited financial results for the quarter ended September 30, 2026 (Q2 FY2027) will be held on Friday, November 6, 2026, from 8:30 am to 9:30 am IST. The filing is a scheduling notice and contains no financial results, so no period-over-period performance figures are disclosed.

  • · Earnings call date: Friday, November 6, 2026, 8:30 am – 9:30 am IST
  • · Earnings call covers unaudited results for the quarter ended September 30, 2026 (Q2 FY2027)
  • · Dial-in numbers provided: Universal access +91 22 6280 1298 / +91 22 7115 8199; toll-free access for USA, UK, Singapore and Hong Kong; online pre-registration available
  • · Filing references NSE Symbol GLENMARK and BSE Scrip Code 532296, ISIN INE935A01035
Dr. Reddy's Laboratories Limited Market Update mixed materiality 7/10

23-10-2026

Dr. Reddy's Laboratories reported consolidated total revenue from operations of ₹86,978 million for the quarter ended 30 September 2026, down 1.5% from ₹88,283 million in the year-ago quarter but up 7.4% sequentially from ₹80,998 million. Consolidated net profit attributable to equity shareholders was ₹9,248 million, down 31.4% YoY from ₹13,471 million, with basic EPS of ₹11.10 versus ₹16.18 a year earlier. Standalone revenue from operations rose 20.6% YoY to ₹55,726 million, while standalone net profit rose 79.6% YoY to ₹6,958 million, though the prior-year quarter included a sharply higher tax-adjusted base.

  • · Consolidated half-year net profit attributable to equity shareholders was ₹13,691 million, down from ₹27,652 million in H1 FY26 (-50.5%).
  • · Consolidated other income fell to ₹1,562 million in the quarter from ₹3,239 million a year earlier (-51.8%).
  • · Consolidated finance costs rose to ₹1,248 million from ₹907 million (+37.6%), and standalone finance costs more than doubled to ₹770 million from ₹334 million.
  • · Standalone other income for the quarter was ₹2,173 million versus ₹3,642 million a year earlier (-40.3%).
  • · Standalone half-year net profit was ₹11,005 million versus ₹33,485 million a year earlier (-67.1%), reflecting a much higher prior-year tax base and profit before tax of ₹13,983 million versus ₹44,526 million.
Dr. Reddy's Laboratories Limited Market Update mixed materiality 8/10

23-10-2026

Dr. Reddy's Laboratories reported Q2FY27 revenues of ₹ 8,671 Cr, up 1.5% YoY and 7% QoQ, with reported EBITDA of ₹ 1,783 Cr (20.6% margin) and PAT of ₹ 925 Cr (10.7%). Management highlighted double-digit growth in its underlying base business excluding lenalidomide in North America, while reported YoY growth was held back by lower lenalidomide sales. Mixed signals remain: Europe and PSAI (API) segments showed weak or flat growth, and the company flagged an ongoing semaglutide API quality issue, several FDA Form 483 observations, and a Form 2953 records assessment.

  • · North America base business (excluding lenalidomide) grew double digits, versus reported YoY decline of 23%, driven by lower lenalidomide sales including a ₹453 Cr shelf stock adjustment impact
  • · Europe revenue was essentially flat YoY (+1%) and PSAI revenue fell 12% YoY, with PSAI gross margin at 9.5% versus 18.0% in Q2FY26
  • · Gross margin improved to 52.1% in Q2FY27 from 46.5% in Q1FY27, but SG&A rose to 32.4% of revenue from 30.0% a year earlier
  • · Reported EBITDA declined 24% YoY despite revenue being broadly stable, with EBITDA margin down from 26.7% to 20.6%
  • · Ongoing regulatory activity includes Form 483 observations at several India facilities (Srikakulam, Bachupally, Pydibhimavaram, Visakhapatnam), a Form 2953 with 2 observations for the Mexico API facility, and a semaglutide API batch quality issue still being resolved
  • · Diluted EPS was ₹11.1 in Q2FY27 versus ₹17.3 in Q2FY26, a decline of roughly 36% YoY
Max Healthcare Institute Limited Corporate Governance neutral materiality 3/10

23-10-2026

Max Healthcare Institute Limited has notified the stock exchanges that its Board of Directors will meet on Friday, October 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The trading window for designated persons and their immediate relatives will remain closed until 48 hours after the results are declared, continuing the closure first intimated on September 25, 2026.

  • · Board meeting date: Friday, October 30, 2026
  • · Trading window closure extends until 48 hours after declaration of results
  • · Filing made under Regulation 29 of SEBI LODR Regulations, 2015
  • · Stock symbol MAXHEALTH; BSE scrip code 543220
Max Healthcare Institute Limited Analyst/Investor Meet neutral materiality 3/10

23-10-2026

Max Healthcare Institute Limited has scheduled an earnings conference call for investors and analysts on Tuesday, November 3, 2026 at 12:00 Noon IST to discuss results for the quarter and half year ended September 30, 2026 (Q2 & H1 FY27). The Q2 & H1 FY27 results are to be declared on Friday, October 30, 2026. The filing contains no financial results figures, so no period-over-period performance can be assessed from this disclosure.

  • · Earnings call scheduled for Tuesday, November 3, 2026 at 12:00 Noon IST, with the Q2 & H1 FY27 results to be declared on Friday, October 30, 2026
  • · Dial-in numbers provided for India, Hong Kong, Singapore, UK and USA, with pre-registration via DiamondPass
  • · Hospitals in Mohali and Bathinda operate under PPP arrangements with the Government of Punjab
  • · Call financial information differs from audited financials and includes Network/partner facilities that may not meet statutory audit requirements
Dr. Reddy's Laboratories Limited Corporate Governance mixed materiality 7/10

23-10-2026

Dr. Reddy's Laboratories reported consolidated IFRS results for Q2 FY27 with revenues of ₹86,708 Mn, down 1.5% YoY but up 7.4% QoQ, and PAT attributable to equity holders of ₹9,250 Mn, down 36% YoY. Results were mixed: EBITDA margin of 20.6% and sequential recovery were positive, while gross margin fell to 52.1% from 54.7% a year earlier and H1 FY27 revenue declined 3.5% YoY. The Board also approved the appointment of Mr. Akhil Ravi, a related party (son-in-law of Co-Chairman G V Prasad), as Head API and Services and Senior Management Personnel effective November 13, 2026.

  • · Gross margin fell to 52.1% in Q2FY27 from 54.7% in Q2FY26 and H1FY27 gross margin was 49.4% versus 55.8% in H1FY26, indicating margin compression not highlighted in the summary.
  • · Q2FY27 Profit before Tax declined about 33% YoY (₹12,277 Mn vs ₹18,350 Mn), with PBT margin at 14.2% versus 20.8% a year earlier.
  • · Q1FY27 results included a ₹2,397 Mn provision related to semaglutide API inventory and associated costs.
  • · Akhil Ravi is a related party as the son-in-law of Co-Chairman and MD G V Prasad; he previously led Aurigene Pharmaceutical Services Ltd. as CEO and his appointment is effective November 13, 2026.
Dr. Reddy's Laboratories Limited Market Notice neutral materiality 4/10

23-10-2026

Dr. Reddy's Laboratories' Board approved the appointment of Mr. Akhil Ravi as Head API and Services and Senior Management Personnel, and his induction into the Management Council, effective November 13, 2026. Mr. Ravi, currently CEO of wholly owned subsidiary Aurigene Pharmaceutical Services Ltd. (APSL), is a related party as the son-in-law of Co-Chairman and Managing Director G V Prasad. The filing contains no financial results or quantitative performance comparisons.

  • · Mr. Akhil Ravi is a related party, being the son-in-law of Co-Chairman and Managing Director G V Prasad
  • · Mr. Akhil Ravi will continue overseeing operations of APSL while taking on the expanded API and Services and Management Council roles
  • · Mr. Ravi holds a PGP from ISB and a B.Tech in Chemical Engineering from IIT Bombay, and previously worked at McKinsey & Company and ITC
  • · The Board meeting commenced at 3:00 p.m. IST and concluded at 4:38 p.m. IST
  • · Disclosure made under Regulation 30 of SEBI LODR, referencing SEBI Master Circular dated January 30, 2026
Torrent Pharmaceuticals Limited Analyst/Investor Meet neutral materiality 2/10

23-10-2026

Torrent Pharmaceuticals Limited has filed a regulatory intimation with BSE and NSE confirming that the audio recording of its conference call with analysts and investors on the financial results for the quarter and half year ended 30 September 2026 has been published on the company website, in line with Regulation 30(6) of the SEBI LODR Regulations, 2015. The filing is administrative in nature and contains no financial figures, operating metrics, or guidance; the underlying results and call commentary are not disclosed in this document.

Cipla Limited Market Update positive materiality 4/10

23-10-2026

Cipla Limited disclosed that the USFDA conducted a routine current Good Manufacturing Practices (cGMP) inspection at the Hauppauge, Long Island, New York facility of InvaGen Pharmaceuticals Inc., its wholly owned subsidiary, from 19 to 22 October 2026. The inspection concluded with zero Form 483 observations. The filing is a Regulation 30 intimation to BSE, NSE and the Luxembourg Stock Exchange.

  • · The inspection was a routine cGMP inspection, not triggered by a specific complaint or enforcement concern.
  • · Inspection period ran from 19 October 2026 to 22 October 2026 (ET).
Lupin Limited Market Notice neutral materiality 3/10

23-10-2026

Lupin Limited has appointed Brian Savage as President and Chief Legal Officer, based in New Jersey, to lead its global Legal, Compliance, and Intellectual Property Management Group. Savage joins from Teva Pharmaceuticals, where he most recently served as Executive Vice President and Interim Global Chief Legal Officer. The filing discloses a management appointment only and contains no financial results, amounts, or percentage changes.

  • · Savage holds a J.D. from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania
  • · Savage has served at Teva since 2015 and previously practiced law at Dechert LLP
  • · Savage led Teva's global litigation strategy and was General Counsel for its U.S. Generics business
Glenmark Pharmaceuticals Limited Corporate Governance neutral materiality 3/10

23-10-2026

Glenmark Pharmaceuticals has scheduled a Board of Directors meeting for Thursday, November 5, 2026, to consider and approve both standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026. The company's trading window for designated persons closed on October 1, 2026, and will remain closed until 48 hours after the results declaration, reopening on Sunday, November 8, 2026. The filing contains no financial performance figures.

  • · Trading window for designated persons (Directors, KMP, identified employees, immediate relatives and connected persons) closed October 1, 2026, per letter dated September 28, 2026
  • · Trading window will remain closed until Saturday, November 7, 2026 and reopen on Sunday, November 8, 2026
  • · Results to be hosted on company website and submitted to exchanges on November 5, 2026, after the board meeting, with newspaper publication to follow under SEBI LODR

Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 14 filings

Start free trial Browse all digests

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE Pharma Sector Regulatory Filings

October 21, 2026

BSE Pharma Sector Regulatory Filings — October 21, 2026

October 20, 2026

BSE Pharma Sector Regulatory Filings — October 20, 2026

October 19, 2026

BSE Pharma Sector Regulatory Filings — October 19, 2026

October 16, 2026

BSE Pharma Sector Regulatory Filings — October 16, 2026

🇮🇳 More from India

View all →

October 23, 2026

India Pre-Market Regulatory Roundup — October 23, 2026

India Pre-Market Regulatory Roundup

October 23, 2026

India Quarterly Results BSE NSE Announcements — October 23, 2026

India Quarterly Results BSE NSE Announcements

October 23, 2026

India Upcoming Corporate Actions BSE NSE — October 23, 2026

India Upcoming Corporate Actions BSE NSE

October 23, 2026

India Merger Acquisition MCA Regulatory Filings — October 23, 2026

India Merger Acquisition MCA Regulatory Filings
← All India digests